Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 6/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10637900 | 0.81 | KDM1A (0.46) | KDM1AHDAC9AKR1B1MEN1KMT2A | |
| SCHEMBL7272186 | 0.81 | ALDH1A1 (0.44) | KDM1AHDAC9AKR1B1KMT2ASIGMAR1 | |
| SCHEMBL10483582 | 0.77 | KDM1A (0.51) | KDM1AAKR1B1MEN1KMT2ASIGMAR1 | |
| SCHEMBL9501252 | 0.76 | KDM1A (0.41) | KDM1AHDAC9AKR1B1MEN1KMT2A | |
| SCHEMBL28136912 | 0.74 | KDM1A (0.45) | KDM1AHDAC9AKR1B1MEN1KMT2A | |
| SCHEMBL28268458 | 0.72 | KDM1A (0.43) | KDM1AHDAC9AKR1B1MEN1KMT2A | |
| SCHEMBL10998922 | 0.72 | HDAC9 (0.46) | KDM1AHDAC9AKR1B1MEN1KMT2A | |
| SCHEMBL11421572 | 0.72 | HDAC9 (0.43) | KDM1AHDAC9AKR1B1MEN1KMT2A | |
| SCHEMBL15848044 | 0.71 | KDM1A (0.53) | KDM1AHDAC9AKR1B1MEN1KMT2A | |
| SCHEMBL6440070 | 0.71 | KDM1A (0.56) | KDM1AAKR1B1MEN1KMT2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070027187-A1 | Hydroxy-tetrahydro-naphthalenylurea derivatives | BAYER HEALTHCARE AG (DE) | 2007-02-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027187-A1 | Hydroxy-tetrahydro-naphthalenylurea derivatives | HVCN1, NMUR1, OPRL1 | KDM1A 2074/4885HDAC9 3182/4885AKR1B1 1029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.